Figure 4.

Ablation of miR-486 and miR-1179 increases cellular migration of thyroid cancer cells. (A, B) Volcano plots comparing log₂ fold change (Log₂FC) with q-value (-log base 10) for miRNAs in the recurrent (REC) THCA cohort vs the nonrecurrent (NON-REC) THCA cohort (A) or normal (B). miRNAs with log₂FC ≥ 0.1 or ≤ −0.1 are shown (A, n = 235; B, n = 432). (C) Box and whisker plots showing expression (log₂) of 4 miRNAs in THCA (REC vs NON-REC) relative to normal. (D) Same as (A) but in the BRAF-like THCA cohort. (E) Volcano plot illustrating log₂FC in THCA (REC vs NON-REC) compared with q-value (-log base 10) for recurrence (high vs low tumoral expression) for 39 differentially expressed miRNAs [(A), P < 0.05]. (F) Representative Kaplan-Meier analysis of disease-free survival for the THCA cohort stratified on high vs low tumoral expression of indicated miRNAs; log-rank test. Number (n) of patients per expression subgroup (high/low), P values, and q-values are shown. (G) Venn diagram showing overlap in the categorization of 23 miRNAs associated with recurrence (E, P < 0.05) and enriched via gene list analysis (ToppGene: microRNAs in cancer and thyroid cancer disease categories). (H) Quantification of scratch wound assays in TPC-1 and SW1736 cells transfected with miRNA mimic (miR-221-5p) and inhibitors (miR-486-5p, miR-1179). %wound recovery determined at indicated time point post-recovery (h). Data presented as mean ± SEM (NS, not significant; **P < 0.01, ***P < 0.001). (I) Relative miR-486 (upper) and miR-221 (lower) expression in TPC-1 and SW1736 cells transfected with the indicated miRNA inhibitor or mimic relative to control.